Effect of Solid Content, Dispersant and Binder Additions on the Drug Loading Properties of Attapulgite in Spray-Dried Microspheres

Abstract

To improve the controlled release ability, we prepared attapulgite into microspheres by spray drying. This research began with a thorough thermogravimetric analysis to optimize attapulgite’s heat treatment for drug loading. By advanced spray drying, attapulgite was transformed into microspheres, refining its drug release characteristics. Various parameters were examined, achieving optimal particle size and morphology at 25% solid content, 2.5% dispersant, and 3% binder. Attapulgite microspheres demonstrated exceptional encapsulation efficiency, exceeding 95% for doxorubicin hydrochloride, highlighting their versatility in drug delivery. FTIR and XRD were used to predict changes in material properties after spray drying. Notably, cytotoxicity tests confirmed the high biocompatibility of attapulgite microspheres, devoid of cell death induction. Attapulgite microsphere loaded with doxorubicin enable sustained drug release and maintain killing ability against tumor cells. This study confirms the viability of spray dried attapulgite microspheres for efficient drug loading and delivery and provides insights for innovative drug delivery systems that utilize the unique properties of attapulgite to advance therapeutics.

Keywords

attapulgite / spray drying / microspheres / cytotoxicity

References

[1] Chen T, Wang J, Qing C, et al.. Effect of Heat Treatment on Structure, Morphology and Surface Properties Palygorskite[J]. Journal of Chinese Ceramic Societies, 2006, 34: 1 406-1 410

[2] Fan G, Shen M. Advances in Research and Application of Attapulgite[J]. Chemical Industry and Engineering Progress, 2009, 28: 99-125

[3] Al-Futaisi A, Jamrah A, Rashid A, et al.. Aspects of Cationic Dye Molecule Adsorption to Palygorskite[J]. Desalination, 2007, 214: 327-342

[4] Wang A. Crystal Structure and Characterization of Attapulgite, Dissociation of Attapulgite Rod Crystal Bundle and Its Nano[J]. Functional Composites, 2015: 146–148

[5] Ye H, Chen F, Sheng Y, et al.. Adsorption of Phosphate from Aqueous Solution onto Modified Palygorskites[J]. Separation and Purification Technology, 2006, 50: 283-290

[6] Wang A. Palygorskite Nanomaterials: Structure, Properties, and Functional Applications, Nanomater[J]. Clay Minerals, 2019, 21: 133

[7] Zhang J, Yuan X. Study on Removal of Phosphate from Waste Water with Alter-attapulgite[J]. China Nonmetallic Minerals Industry, 2010, 5: 41-43

[8] Chen X, Yan G, Chen M, et al.. Alkylated Chitosan-Attapulgite Composite Sponge for Rapid Hemostasis[J]. Biomaterials Advances, 2023, 153: 213 569

[9] Bao P, Du H, Xu X, et al.. Adsorption of Cr (VI) onto Attapulgite/UiO-66-NH₂ Composites from Aqueous Solution[J]. Integrated Ferroelectrics, Taylor & Francis, 2020, 209(1): 125-134

[10] Guo H, Xia K, Cao M, et al.. Surface Modification of Attapulgite by Grafting Cationic Polymers for Treating Dye Wastewaters[J]. Materials, 2021, 14(4792

[11] Zhang H, Yang F, Zhang Q, et al.. Structural Evolution of Palygorskite as the Nanocarrier of Silver Nanoparticles for Improving Antibacterial Activity[J]. ACS Applied Bio Materials, 2022, 5(83 960-3 971

[12] Santos A C, Ferreira C, Veiga F, et al.. Halloysite Clay Nanotubes for Life Sciences Applications: From Drug Encapsulation to Bioscaffold[J]. Advances in Colloid and Interface Science, 2018, 257: 58-70

[13] Wang Z, Zhao Y, Shen M, et al.. Antitumor Efficacy of Doxorubicin-Loaded Electrospun Attapulgite-Poly(lactic-co-glycolic acid) Composite Nanofibers[J]. Journal of Functional Biomaterials, 2022, 13(2): 55

[14] Jaime-Escalante B, Melgoza-Contreras L M, Leyva-Gómez G, et al.. Synthesis and Drug Loading Improvements on Mesoporous SBA-15 by Spray Drying[J]. Drug Development and Industrial Pharmacy, 2021, 47(121 895-1 903

[15] Pandit A, Zeugolis D. Twenty-five Years of Nano-biomaterials: Have We Revolutionized Healthcare[J]. Nanomedicine, 2016, 11: 985-987

[16] Vargason AM, Anselmo AC, Mitragotri S. The Evolution of Commercial Drug Delivery Technologies[J]. Nature Biomedical Engineering, 2021, 5: 951-967

[17] Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions[J]. Molecules, 2021, 26: 279-284

[18] Khalid A, Persano S, Shen H, et al.. Strategies for Improving Drug Delivery: Nanocarriers and Microenvironmental Priming[J]. Expert Opinion on Drug Delivery, 2016, 14: 865-877

[19] Hillery A, Park K. Drug Delivery: Fundamentals and Applications, 2016, Boca Raton, CRC Press M]

[20] Lee PI, Li J-X. Evolution of Oral Controlled Release Dosage Forms[J]. Oral Controlled Release Formulation Design and Drug Delivery, 2010, 5: 21-31

[21] Yun Y, Lee BK, Park K. Controlled Drug Delivery Systems: the Next 30 Years[J]. Frontiers of Chemical Science And Engineering, 2014, 8: 276-279

[22] Ren W, Zhang X, Li W, et al.. Circulating and Tumor-infiltrating Arginase 1-expressing Cells in Gastric Adenocarcinoma Patients Were Mainly Immature and Monocytic Myeloid-derived Suppressor Cells[J]. Sci. Rep., 2020, 10(1): 8 056

[23] Li F, Sun Y, Huang J, et al.. CD4/CD8 + T Cells, DC Subsets, Foxp3, and IDO Expression are Predictive Indictors of Gastric Cancer Prognosis[J]. Cancer Med., 2019, 8(177 330-7 344

[24] Jiang Y, Zhang Q, Hu Y, et al.. ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer[J]. Ann. Surg., 2018, 267(3): 504-513

[25] Angelova M, Mlecnik B, Vasaturo A, et al.. Evolution of Metastases in Space and Time under Immune Selection[J]. Cell, 2018, 175(3): 751-765.e16

[26] Green AE & Rose PG. Pegylated Liposomal Doxorubicin in Ovarian Cancer[J]. Nanomedicine, 2006: 229–239

[27] Chanan-Khan AA & Lee K. Pegylated Liposomal Doxorubicin and Immunomodulatory Drug Combinations in Multiple Myeloma: Rationale and Clinical Experience[J]. Clin. Lymphoma Myeloma, 2007, S163–S169

[28] Sparreboom A. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-free, Nanoparticle Albumin-bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (T axol)[J]. Clin. Cancer Res., 2005, 11: 4 136-4 143

[29] Gradishar WJ. Phase III Trial of Nanoparticle Albumin-bound Paclitaxel Compared with Polyethylated Castor Oil-based Paclitaxel in Women with Breast Cancer[J]. J. Clin. Oncol., 2005, 23: 7 794-7 803

[30] Henderson IC. Nab-paclitaxel for Breast Cancer: A New Formulation with an Improved Safety Profile and Greater Efficacy. Expert Rev[J]. Anticancer Ther., 2020, 7: 919-943

RIGHTS & PERMISSIONS

Wuhan University of Technology and Springer-Verlag GmbH Germany, Part of Springer Nature